Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6781993 | 0.82 | KDM4E (0.56) | GAAKDM4EPOLBHTTALDH1A1 | |
| SCHEMBL29951344 | 0.81 | GAA (0.59) | GAAKDM4EPOLBHTTALDH1A1 | |
| SCHEMBL21649334 | 0.79 | ALDH1A1 (0.37) | GAAKDM4EPOLBALDH1A1LMNA | |
| SCHEMBL6582728 | 0.79 | KDM4E (0.67) | GAAKDM4EPOLBHTTALDH1A1 | |
| SCHEMBL31335674 | 0.78 | GAA (0.54) | GAAKDM4EPOLBHTTALDH1A1 | |
| SCHEMBL28707342 | 0.78 | GAA (0.64) | GAAKDM4EPOLBHTTALDH1A1 | |
| SCHEMBL24329339 | 0.77 | GAA (0.50) | GAAKDM4EPOLBHTTALDH1A1 | |
| SCHEMBL166802 | 0.77 | GAA (0.50) | GAAKDM4EPOLBHTTALDH1A1 | |
| SCHEMBL11385067 | 0.77 | GAA (0.63) | GAAKDM4EPOLBHTTALDH1A1 | |
| SCHEMBL1918973 | 0.77 | GAA (0.50) | GAAKDM4EPOLBHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738653-B2 | Fused furans for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738653-B2 | Fused furans for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738653-B2 | Fused furans for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2970174-B1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2970174-B1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-28 | — | — | US | disclosed |
| EP-2970174-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014159559-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159559-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2539340-B1 | PYRAZOLOPYRIDAZINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2539340-A1 | PYRAZOLOPYRIDAZINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8324212-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120046294-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-23 | — | — | US | disclosed |
| WO-2011106340-A1 | PYRAZOLOPYRIDAZINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, GOT1 | GAA 1059/4885KDM4E 4204/4885POLB 2615/4885 |
| US-20120046294-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | GAA 162/4885KDM4E 4218/4885POLB 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.